In vivo molecular MRI imaging of prostate cancer by targeting PSMA with polypeptide-labeled superparamagnetic iron oxide nanoparticles

International Journal of Molecular Sciences

Volumn 16, Issue 5, 2015, Pages 9573-9587

  Zhu, Yunkai ^a   Sun, Ying ^b   Chen, Yaqing ^a   Liu, Weiyong ^a   Jiang, Jun ^a   Guan, Wenbin ^a   Zhang, Zhongyang ^a   Duan, Yourong ^b  

^a XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Molecular imaging; MRI; Polypeptide; Prostate neoplasms; PSMA; SPIONs

Indexed keywords

FERRIC FERROCYANIDE; POLYGLACTIN; POLYPEPTIDE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; CONTRAST MEDIUM; FERRIC ION; FERRIC OXIDE; FERROCYANIDE; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; LACTIC ACID; MEMBRANE ANTIGEN; METAL NANOPARTICLE; PEPTIDE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; PROTEIN BINDING;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BINDING ASSAY; CANCER TISSUE; CELL LINE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROSCOPY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSTATE CANCER; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CHEMISTRY; NANOTECHNOLOGY; NUDE MOUSE; PATHOLOGY; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

MUS;

ANIMALS; ANTIGENS, SURFACE; CELL LINE, TUMOR; CONTRAST MEDIA; FERRIC COMPOUNDS; FERROCYANIDES; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; LACTIC ACID; MAGNETIC RESONANCE IMAGING; MALE; METAL NANOPARTICLES; MICE; MICE, INBRED BALB C; MICE, NUDE; NANOTECHNOLOGY; NEOPLASM TRANSPLANTATION; PEPTIDES; POLYGLYCOLIC ACID; PROSTATIC NEOPLASMS; PROTEIN BINDING; SIGNAL TRANSDUCTION;

EID: 84929299321     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms16059573     Document Type: Article

References (25)

1. Siegel, R.; Ma, J.; Zou, Z.; Jemal A. Cancer statistics. CA Cancer J. Clin. 2014, 64, 9–29.
2. Ukimura, O.; Faber, K.; Gill, I.S. Intraprostatic targeting. Curr. Opin. Urol. 2012, 22, 97–103.
3. Turkbey, B.; Albert, P.S.; Kurdziel, K.; Choyke, P.L. Imaging localized prostate cancer: Current approaches and new developments. Am. J. Roentgenol. 2009, 192, 1471–1480.
4. De Nunzio, C.; Kramer, G.; Marberger, M.; Montironi, R.; Nelson, W.; Schroder, F.; Sciarra, A.; Tubaro, A. The controversial relationship between benign prostatic hyperplasia and prostate cancer: The role of inflammation. Eur. Urol. 2011, 60, 106–117.
5. Blomqvist, L.; Carlsson, S.; Gjertsson, P.; Heintz, E.; Hultcrantz, M.; Mejare, I.; Andren, O. Limited evidence for the use of imaging to detect prostate cancer: A systematic review. Eur. J. Radiol. 2014, 83, 1601–1606.
6. Tilki, D.; Seitz, M.; Singer, B.B.; Irmak, S.; Stief, C.G.; Reich, O.; Ergun, S. Molecular imaging of tumor blood vessels in prostate cancer. Anticancer Res. 2009, 29, 1823–1829.
7. Ghosh, A.; Heston, W.D. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J. Cell. Biochem. 2004, 91, 528–539.
8. Schmittgen, T.D.; Teske, S.; Vessella, R.L.; True, L.D.; Zakrajsek, B.A. Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients. Int. J. Cancer 2003, 107, 323–329.
9. Rajasekaran, S.A.; Anilkumar, G.; Oshima, E.; Bowie, J.U.; Liu, H.; Heston, W.; Bander, N.H.; Rajasekaran, A.K. A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. Mol. Biol. Cell 2003, 14, 4835–4845.
10. Ren, J.; Zhang, Z.; Wang, F.; Yang, Y.; Liu, Y.; Wei, G.; Yang, A.; Zhang, R.; Huan, Y.; Cui, Y. et al. MRI of prostate stem cell antigen expression in prostate tumors. Nanomedicine 2012, 7, 691–703.
11. Wang, Z.; Cuschieri, A. Tumour cell labelling by magnetic nanoparticles with determination of intracellular iron content and spatial distribution of the intracellular iron. Int. J. Mol. Sci. 2013, 14, 9111–9125.
12. Taylor, R.M.; Huber, D.L.; Monson, T.C.; Ali, A.M.; Bisoffi, M.; Sillerud, L.O. Multifunctional iron platinum stealth immunomicelles: Targeted detection of human prostate cancer cells using both fluorescence and magnetic resonance imaging. J. Nanopart. Res. 2011, 13, 4717–4729.
13. Islam, T.; Josephson, L. Current state and future applications of active targeting in malignancies using superparamagnetic iron oxide nanoparticles. Cancer Biomark. 2009, 5, 99–107.
14. Bates, D.; Abraham, S.; Campbell, M.; Zehbe, I.; Curiel, L. Development and characterization of an antibody-labeled super-paramagnetic iron oxide contrast agent targeting prostate cancer cells for magnetic resonance imaging. PLoS ONE 2014, 9, e97220.
15. Abdolahi, M.; Shahbazi-Gahrouei, D.; Laurent, S.; Sermeus, C.; Firozian, F.; Allen, B.J.; Boutry, S.; Muller, R.N. Synthesis and in vitro evaluation of MR molecular imaging probes using J591 mAb-conjugated SPIONs for specific detection of prostate cancer. Contrast Media Mol. Imaging 2013, 8, 175–184.
16. Kasten, B.B.; Liu, T.; Nedrow-Byers, J.R.; Benny, P.D.; Berkman, C.E. Targeting prostate cancer cells with PSMA inhibitor-guided gold nanoparticles. Bioorg. Med. Chem. Lett. 2013, 23, 565–568.
17. Tagawa, S.T.; Beltran, H.; Vallabhajosula, S.; Goldsmith, S.J.; Osborne, J.; Matulich, D.; Petrillo, K.; Parmar, S.; Nanus, D.M.; Bander, N.H. Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer 2010, 116, 1075–1083.
18. Frigerio, B.; Fracasso, G.; Luison, E.; Cingarlini, S.; Mortarino, M.; Coliva, A.; Seregni, E.; Bombardieri, E.; Zuccolotto, G.; Rosato A. et al. A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer. Eur. J. Cancer 2013, 49, 2223–2232.
19. Wu, X.; Yu, G.; Lindner, D.; Brady-Kalnay, S.M.; Zhang, Q.; Lu, Z.R. Peptide targeted high-resolution molecular imaging of prostate cancer with MRI. Am. J. Nucl. Med. Mol. Imaging 2014, 4, 525–536.
20. Tan, M.; Burden-Gulley, S.M.; Li, W.; Wu, X.; Lindner, D.; Brady-Kalnay, S.M.; Gulani, V.; Lu, Z.R. MR molecular imaging of prostate cancer with a peptide-targeted contrast agent in a mouse orthotopic prostate cancer model. Pharm. Res. 2012, 29, 953–960.
21. Lupold, S.E.; Rodriguez, R. Disulfide-constrained peptides that bind to the extracellular portion of the prostate-specific membrane antigen. Mol. Cancer Ther. 2004, 3, 597–603.
22. Tse, B.W.; Cowin, G.J.; Soekmadji, C.; Jovanovic, L.; Vasireddy, R.S.; Ling, M.T.; Khatri, A.; Liu, T.; Thierry, B.; Russell, P.J. PSMA-targeting iron oxide magnetic nanoparticles enhance MRI of preclinical prostate cancer. Nanomedicine 2014, 19, 1–12.
23. Ittrich, H.; Peldschus, K.; Raabe, N.; Kaul, M.; Adam, G. Superparamagnetic iron oxide nanoparticles in biomedicine: Applications and developments in diagnostics and therapy. Rofo 2013, 185, 1149–1166.
24. Liu, X.; Kaminski, M.D.; Chen, H.; Torno, M.; Taylor, L.; Rosengart, A.J. Synthesis and characterization of highly-magnetic biodegradable poly(D,L-lactide-co-glycolide) nanospheres. J. Control. Release 2007, 119, 52–58.
25. Yu, M.K.; Kim, D.; Lee, I.H.; So, J.S.; Jeong, Y.Y.; Jon, S. Image-guided prostate cancer therapy using aptamer-functionalized thermally cross-linked superparamagnetic iron oxide nanoparticles. Small 2011, 7, 2241–2249.